Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
GAO assails FDA's foreign inspections
Oh, woe is the FDA. The Government Accountability Office is set to release a new report on the agency's terrifically inadequate inspection record overseas. According to the New York Times, which obtained a copy early, the FDA is so understaffed that it would need at least 27 years to inspect every foreign medical device plant and 13 years to check every foreign drug plant. Think that's bad? Catching up on food inspections would take a mind-boggling 1,900 years.
Most disturbing is the fact that the agency is farthest behind in--you guessed it--China, that bastion of impure and unsafe exports. China has more drug and device plants than any other foreign nation, and FDA inspections there are few, the Times notes.
The GAO will present this bad news at a hearing before the House Energy and Commerce Committee, which has been dogging the FDA for months now. One witness set to testify said, "This is a fundamentally broken agency, and it needs to be repaired." We advise the FDA to focus on the "repair" part of that sentence. Today will be painful, sure, but it could lead to a sorely needed increase in funding. If the stars and politicians line up just right, that is.
- read the article from the New York Times
- here's the witness list (.pdf) for today's hearing; find a link to the webcast
Related Articles:
FDA wants satellite offices overseas
FDA badly needs more money, staff
FDA can't guarantee drug safety
Overseas drugmaking goes unsupervised
Comments
Keep manufacturing in the USA. Stop China imports. Cut costs in USA. Bring jobs back to USA>
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


